Vir Biotechnology, Inc. Restructuring and Related Cost, Number of Positions Eliminated
Vir Biotechnology, Inc. (VIR) reported Restructuring and Related Cost, Number of Positions Eliminated of 75 position for the 1-month period ending 2023-12-31, per its 10-Q filed 2024-08-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2024-08-01
- 2023-12-31: Restructuring and Related Cost, Number of Positions Eliminated 1 month 75.00 position.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 1 month |
|---|---|
| 2023-12-31 | 75.00 position 10-Q · filed 2024-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |